A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers

Psychiatry Res. 2011 Apr 30;186(2-3):431-6. doi: 10.1016/j.psychres.2010.09.019. Epub 2010 Oct 23.

Abstract

Early mechanisms to limit the input of sensory information to higher brain areas are important for a healthy individual. In previous studies, we found that a low dose of 10mg escitalopram (SSRI) disrupts habituation, without affecting sensory and sensorimotor gating in healthy volunteers. In the current study a higher dose of 15 mg was used. The hypothesis was that this higher dose of escitalopram would not only disrupt habituation, but also sensory and sensorimotor gating. Twenty healthy male volunteers received either placebo or 15 mg escitalopram, after which they were tested in a P50 suppression, and a habituation and prepulse inhibition (PPI) of the startle reflex paradigm. Escitalopram significantly decreased P50 suppression and habituation, but had no effect on PPI. The results indicate that habituation and sensory gating are disrupted by increased serotonergic activity, while sensorimotor gating seems relatively insensitive to such a rise. Since the patients who are frequently treated with SSRIs (patients with schizophrenia and affective disorders) might already suffer from disrupted sensory gating and habituation, the current results call for caution in the determination of a proper dose.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acoustic Stimulation / methods
  • Adolescent
  • Adult
  • Analysis of Variance
  • Antidepressive Agents, Second-Generation / pharmacology*
  • Citalopram / pharmacology*
  • Cross-Over Studies
  • Double-Blind Method
  • Electroencephalography
  • Evoked Potentials, Auditory / drug effects
  • Habituation, Psychophysiologic / drug effects*
  • Humans
  • Male
  • Neural Inhibition / drug effects
  • Reflex, Startle / drug effects
  • Sensory Gating / drug effects*
  • Young Adult

Substances

  • Antidepressive Agents, Second-Generation
  • Citalopram